PMID- 36066352
OWN - NLM
STAT- MEDLINE
DCOM- 20221011
LR  - 20230727
IS  - 1728-7731 (Electronic)
IS  - 1726-4901 (Linking)
VI  - 85
IP  - 10
DP  - 2022 Oct 1
TI  - To do one and to get more: Part I. Diabetes and bone.
PG  - 965-971
LID - 10.1097/JCMA.0000000000000803 [doi]
AB  - Type 2 diabetes mellitus (T2DM), is a chronic metabolic disease, characterized by 
      the presence of hyperglycemia and insulin resistance. The key treatment 
      strategies for T2DM include modification of lifestyle, medications, and 
      continuous glucose monitoring. DM patients often have DM-associated morbidities 
      and comorbidities; however, disorders of musculoskeletal system are often 
      neglected, compared to other major systems in DM patients. Based on sharing 
      similar pathophysiology of DM and osteoporosis, it is supposed that the use of 
      antidiabetic agents (ADAs) may not only provide the lowering glucose level effect 
      and the maintenance of the sugar homeostasis to directly delay the tissue damage 
      secondary to hyperglycemia but also offer the benefits, such as the prevention of 
      developing osteoporosis and fractures. Based on the current review, evidence 
      shows the positive correlation between DM and osteoporosis or fracture, but the 
      effectiveness of using ADA in the prevention of osteoporosis and subsequent 
      reduction of fracture seems to be inconclusive. Although the benefits of ADA on 
      bone health are uncertain, the potential value of "To do one and to get more" 
      therapeutic strategy should be always persuaded. At least, one of the key 
      treatment strategies as an establishment of healthy lifestyle may work, because 
      it improves the status of insulin resistance and subsequently helps DM control, 
      prevents the DM-related micro- and macrovascular injury, and possibly strengthens 
      the general performance of musculoskeletal system. With stronger musculoskeletal 
      system support, the risk of "fall" may be decreased, because it is associated 
      with fracture. Although the ADA available in the market does not satisfy the 
      policy of "To do one and to get more" yet, we are looking forward to seeing the 
      continuously advanced technology of drug development on diabetic control, and 
      hope to see their extra-sugar-lowering effects.
CI  - Copyright (c) 2022, the Chinese Medical Association.
FAU - Lee, Wen-Ling
AU  - Lee WL
AD  - Department of Medicine, Cheng-Hsin General Hospital, Taipei, Taiwan, ROC.
AD  - Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, 
      Taiwan, ROC.
AD  - Department of Nursing, Oriental Institute of Technology, New Taipei City, Taiwan, 
      ROC.
FAU - Wang, Peng-Hui
AU  - Wang PH
AD  - Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, 
      Taiwan, ROC.
AD  - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, 
      Taipei, Taiwan, ROC.
AD  - Department of Medical Research, China Medical University Hospital, Taichung, 
      Taiwan, ROC.
AD  - Female Cancer Foundation, Taipei, Taiwan, ROC.
FAU - Yang, Szu-Ting
AU  - Yang ST
AD  - Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, 
      Taiwan, ROC.
AD  - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, 
      Taipei, Taiwan, ROC.
FAU - Liu, Chia-Hao
AU  - Liu CH
AD  - Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, 
      Taiwan, ROC.
AD  - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, 
      Taipei, Taiwan, ROC.
FAU - Chang, Wen-Hsun
AU  - Chang WH
AD  - Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, 
      Taipei, Taiwan, ROC.
AD  - Department of Nursing, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
FAU - Lee, Fa-Kung
AU  - Lee FK
AD  - Department of Obstetrics and Gynecology, Cathy General Hospital, Taipei, Taiwan, 
      ROC.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220906
PL  - Netherlands
TA  - J Chin Med Assoc
JT  - Journal of the Chinese Medical Association : JCMA
JID - 101174817
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Blood Glucose
MH  - Blood Glucose Self-Monitoring
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Fractures, Bone/complications
MH  - Humans
MH  - *Hyperglycemia/complications
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Insulin Resistance
MH  - *Osteoporosis/complications/prevention & control
COIS- Conflicts of interest: Dr. Peng-Hui Wang, an editorial board member at Journal of 
      the Chinese Medical Association, had no role in the peer review process of or 
      decision to publish this article. The other authors declare that they have no 
      conflicts of interest related to the subject matter or materials discussed in 
      this article.
EDAT- 2022/09/07 06:00
MHDA- 2022/10/12 06:00
CRDT- 2022/09/06 09:53
PHST- 2022/09/07 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
PHST- 2022/09/06 09:53 [entrez]
AID - 02118582-202210000-00002 [pii]
AID - 10.1097/JCMA.0000000000000803 [doi]
PST - ppublish
SO  - J Chin Med Assoc. 2022 Oct 1;85(10):965-971. doi: 10.1097/JCMA.0000000000000803. 
      Epub 2022 Sep 6.